The goal of this clinical trial is to find out if a gut cleaning using Rifaximin works as well as the usual treatment with Neomycin and Metronidazole to prevent infections after colon surgery. The study includes adult patients who will have colon surgery.
The main question it aims to answer are:
-Does the Rifaximin treatment prevent surgical site infections as well as the Neomycin/Metronidazole treatment?
Other things the study will look at:
* How often infections happen, stratified on how deep they are, the type of surgery the patients got, or if bowel cleaning was done before surgery.
* How many people will die after surgery
* How long people stay in hospital
Participants will:
* Take either Rifaximin or Neomycin/Metronidazole one day before surgery to clean their gut
* Keep a diary until the surgery to record medication intake and any side effects
* Be contacted by phone 30 days after surgery to ask about their condition and any side effects,

Start Date01 Jun 2026

Sponsor / Collaborator

Universität Luzern

ChiCTR2600120985

/ Not yet recruitingNot ApplicableIIT

Rifaximin for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with minimal hepatic encephalopathy: A randomized controlled study

Start Date01 Apr 2026

Sponsor / Collaborator

Southeast University Affiliated Zhonda Hospital

NCT07454408

/ Not yet recruitingPhase 1/2IIT

A Clinical Randomized Controlled Study on the Prevention and Treatment of Drug-refractory Hepatic Encephalopathy After TIPS With Fecal Microbiota Transplantation

This study is a randomized, placebo-controlled, exploratory phase II clinical trial led by Professor Han Gyeong-ho from the Digestive Disease Hospital of Xi'an International Medical Center. The study enrolled 40 patients who had experienced recurrence of hepatic encephalopathy despite treatment with rifaximin and lactulose. These patients were randomly divided 1:1 into the experimental group and the control group. After obtaining informed consent from the patients, fecal microbiota transplantation or placebo control was performed. The fecal microbiota was sourced from the feces of healthy individuals who had a rich composition of the Muribaculaceae, Ruminococcaceae, and Bifidobacteriaceae families and did not contain pathogenic bacteria. The safety and efficacy of the treatment were followed up, and blood and fecal samples were collected for sequencing analysis. The aim was to provide new solutions for patients with hepatic encephalopathy who did not respond to the treatment with rifaximin and lactulose after TIPS surgery; and to explore the impact of microbiota changes and translocation on the recurrence of hepatic encephalopathy after TIPS surgery.

Start Date07 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Rifaximin

100 Translational Medicine associated with Rifaximin

100 Patents (Medical) associated with Rifaximin

1,752

Literatures (Medical) associated with Rifaximin

06 Mar 2026·LETTERS IN APPLIED MICROBIOLOGY

Assessment of rifaximin and rifampicin resistance across Clostridioides difficile ribotypes: a systematic review and meta-analysis

Review

Author: Alanazi, Reem Khader ; Alqarni, Yousef Saeed ; Alabbad, Rawan ; Alkhushaym, Nasser ; Almalki, Naif ; Alhifany, Abdullah

Abstract:

Clostridioides difficile is an opportunistic pathogen of the gastrointestinal tract that can cause illnesses ranging from diarrhea to pseudomembranous colitis. Recurrent Clostridioides difficile infection remains a major clinical challenge, with substantial relapse rates after standard antibiotic therapy. Emerging evidence suggests that rifaximin can be used after the conventional therapy to reduce risk of the recurrence. However, rifaximin resistance in Clostridioides difficile remains the primary concern. The aim of this systematic review and meta-analysis is to estimate the risk of rifaximin resistance in Clostridioides difficile infection and among different ribotypes. The search included PubMed, Scopus, Web of Science, and Cochrane Library for studies reporting rifaximin resistance in Clostridioides difficile isolates. After systematically screening 731 records from all databases and excluding 664 studies, a total of 67 studies were included in the meta-analysis. The findings of the meta-analaysis indicated a resistance rate of 15.1% (95% CI, 12.0%–18.9%) for rifaximin and/or rifampicin and 12.8% (95% CI, 8.8%–18.2%) for rifaximin alone. Ribotype-specific analysis revealed high rifaximin resistance in RT017 (72.3%), RT027 (47.0%), and RT018 (20.9%), while RT012, RT002, RT112, and RT014/020 demonstrated low resistance. The study finding indicate that rifaximin/rifamycin resistance in Clostridioides difficile is concerning and not randomly distributed but is more frequently associated with certain ribotypes.

01 Mar 2026·Pakistan Journal of Pharmaceutical Sciences

Azathioprine Combined With Either Rifaximin (A Microecological Inhibitor) Or Infliximab For Inflammatory Bowel Disease: Differential Impacts On Intestinal Barrier Function, Inflammatory Response And Stress Injury

Article

Author: Gong, Yuanxiang ; Guo, Jia ; Zhang, Peisong ; Han, Renda

Background: Inflammatory bowel disease (IBD) is an immune-related chronic intestinal inflammatory disease. In recent years, the incidence of IBD has increased significantly and the trend of younger age is obvious. Objectives: This prospective cohort study compared the effects of microecological inhibitors (rifaximin, RIF) plus azathioprine (AZA) versus infliximab (IFX) plus AZA in patients with active IBD. Methods: A total of 130 patients were randomized into two groups and treated for 12 weeks. Key outcomes included intestinal barrier function [Diamine oxidase (DAO), Fecal calprotectin (FC), Lipopolysaccharide (LPS)], mucosal repair markers [Epidermal growth factor (EGF), Transforming growth factor-?1 (TGF-?1)], inflammatory factors [Interleukin-6 (IL-6) and Tumor necrosis factor-? (TNF-?), C reactive protein (CRP)] and oxidative stress indices [Superoxide dismutase (SOD), Malondialdehyde (MDA)]. Results: IFX+AZA rapidly reduced pro-inflammatory cytokines (TNF-? decreased, CRP increased) and mucosal injury markers (DAO increased), but elevated LPS levels (P<0.05). In contrast, RIF + AZA enhanced mucosal repair (EGF decreased, TGF-?1 decreased) and antioxidant capacity (SOD decreased, MDA increased), with less liver enzyme elevation. The study suggests IFX + AZA is superior for acute inflammation control via TNF-? inhibition, while RIF + AZA offers long-term benefits in mucosal healing and oxidative balance through microbiota modulation. Conclusion: IFX + AZA for rapid induction remission and RIF+AZA for maintenance therapy in IBD

01 Mar 2026·AMERICAN JOURNAL OF GASTROENTEROLOGY

The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Review

Author: Busam, Jonathan A. ; Pimentel, Mark ; Rezaie, Ali ; Marshall, Caroline ; Joo, LiJin ; Batta, Nisha ; Shah, Eric D.

INTRODUCTION::

Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments.

METHODS::

PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug.

RESULTS::

Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 ( P < 0.01), 53 ( P = 0.59), 59 ( P < 0.01), 58 ( P = 0.03), and 16 ( P < 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 ( P < 0.01) and 32 ( P < 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 ( P < 0.01). Many AEs were transient without long-term sequela.

DISCUSSION::

Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.

115

News (Medical) associated with Rifaximin

31 Mar 2026

·www.biospace.com

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA 2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026). BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of strategic evolution and solid performance of key brands – all contributing to market share growth. Despite its voluntary withdrawal of Ocaliva® from the US market, Alfasigma delivered strong performance through its disciplined investment strategy and effective execution, unlocking opportunities and building momentum across its key therapeutic areas (gastroenterology, vascular & immunology) and consumer healthcare. Growing Performance Across Products and Markets Alfasigma saw double-digit growth from many of its brands namely Vessel®, Normix® and Jyseleca® and the Esoxx (reflux) brand family. Similarly, Alfasigma saw significant growth across its Growth Markets (+15% vs PY) and Western Europe (+11% 1 vs PY) segments, from investments in expanded commercial teams, targeted media spend, and new affiliates leading to the increase in market share. Over 2025, the Company added new locations (KSA and Hungary) bringing its products to more patients worldwide. Continued investments to expand Innovative Portfolio Investment partnerships were announced following the reporting period, including the March 2026 agreement with GSK plc for the worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). Subsequently granted approval by the US FDA becoming the first medicine approved in the US for this indication. The approval, based on the positive GLISTEN phase III trial, provides immediate commercialisation opportunities in the US, with regulatory reviews underway in the EU, UK, Canada and China 3 . Additionally, in January 2026, Alfasigma announced its investment in Innovative Molecules, obtaining the exclusive worldwide license to the parenteral formulation of adibelivir for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life-threatening condition. The company is well-positioned to drive future organic growth as well through expanding its pipeline of opportunities. This includes delivering on the full potential of Jyseleca®, with application submitted following the reporting period, and being under review by EMA for the use of Jyseleca® in a new indication of treatment for axial spondyloarthritis (axSpA), a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing chronic pain and stiffness that often begins in early adulthood. A disease with high prevalence in Europe, only around 40-50% of patients with axSpA achieve an adequate response with current advanced therapies, highlighting significant unmet needs. Chairman Stefano Golinelli stated, “ I am proud of our progress over 2025. We delivered solid results, advancing our strategy to drive sustainable growth and to develop meaningful solutions to patients worldwide. Alfasigma’s continued investment in innovation, partnerships, talent, capabilities, and our portfolio, positions the Company for even greater success in the years ahead .” CEO Francesco Balestrieri commented, “ Our 2025 financial results are testament to Alfasigma’s strategic direction, reflecting the strength of our existing and expanding product portfolio, particularly across Growth Markets. The US and Italy remain important markets, and the Company’s performance shows that where we invest, we grow. We are financially strong and well-capitalised, underpinning our capacity to invest across key markets and products with potential – at pace and with agility – as we advance our portfolio for continued profitable growth .” Capitalised for Future Growth Over 2025, Alfasigma completed successful financing rounds to support its R&D, and to accelerate growth, transformation, and global expansion. This included, but was not limited to, European Investment Bank and SACE, as well as several Italian private banks. Forward Momentum and Sustainable Growth Looking ahead, Alfasigma is well-placed to capitalise on its 2025 performance. Today, the company is in a significantly stronger position, with revamped growth in Consumer Healthcare and Established platforms, as well as new Rare and Specialty platforms. Leveraging its portfolio and growing presence across markets worldwide, Alfasigma is equipped to drive future growth and offer significant headroom for value creation through a disciplined M&A strategy. About Alfasigma Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered today in Bologna and Milan. The Group’s products are distributed in more than 100 markets worldwide. Alfasigma operates offices across major European countries, as well as in the United States, China, and Mexico; production facilities in Italy, Spain, and the United States; and R&D laboratories located in Italy. The company employs approximately 4,000 professionals dedicated to the research, development, production, and distribution of medicinal products. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic areas including gastroenterology, vascular health, and immunology. 1 Like-for-like comparison considering Jyseleca® business acquisition timing in 2024. 2 Adjusted EBITDA - adjusted EBITDA excludes the impact of restructuring costs and selected items related to Jyseleca® business acquisition. 3 This transaction is ongoing and is subject to customary conditions, including applicable regulatory agency clearances such as under the Hart-Scott-Rodino Act in the US. Contacts For further information, contact: Global Press office: Tristan Peniston-Bird tristan.peniston-bird@omc.com Irene Lawlor Irene.Lawlor@alfasigma.com

Drug ApprovalLicense out/inPhase 3BiosimilarFinancial Statement

19 Mar 2026

·www.businesswire.com

New Drug Cost Study: Canadian Online Pharmacies Offer Up to 89% Savings Versus GoodRx and Amazon for U.S. Consumers, Says Campaign for Personal Prescription Importation

HILLSBOROUGH, N.J.--(BUSINESS WIRE)--The Campaign for Personal Prescription Importation (CPPI), a non-profit advocate for affordable access to prescription medications, has released a new price comparison study highlighting the stark differences between U.S. and Canadian pharmacy prices for popular brand-name prescription drugs. We’re in an affordability epidemic. With the ability to personally import essentially identical medications from Canada, U.S. consumers can find desperately needed relief. Using data researched in Mar. 2026, CPPI’s analysis shows that for a sample of 10 popular, name-brand prescription medicines – all daily maintenance medications for common conditions – U.S. consumers can save 52% to 89% by purchasing from licensed Canadian online pharmacies. These results show personal importation from Canada continues to be a significant option for those facing exorbitantly high drug costs. America in a Drug “Affordability Epidemic” CPPI’s study underscores how U.S. prescription costs outpace affordability – as a great number of Americans are dangerously non-compliant with their drug therapy. For instance, a recent survey from the Kaiser Family Foundation (KFF) reveals that about one in five adults (21%) have not filled a prescription due to cost. Additionally, the KFF survey finds about one in seven adults say they have cut pills in half or skipped doses of medicine in the last year because of the cost. “These results highlight the ongoing need for easily accessible alternatives to notoriously high U.S. pharmaceutical prices. We’re in an affordability epidemic,” said CPPI’s Executive Director Ken Hunter. “Millions of Americans are on fixed incomes, have high-deductible health plans that skyrocketed in price when Affordable Care Act subsidies ended in December, or can’t afford insurance at all. With the ability to personally import essentially identical medications from Canada, consumers can find desperately needed relief.” CPPI’s findings, drawn from research comparing GoodRx and Amazon prices in the U.S. against Canadian equivalents, demonstrate average savings of over 64% across 10 commonly prescribed brand-name drugs. These include treatments for conditions including Type 2 diabetes, blood clots, and overactive bladder. Top savings examples for 90-day supplies include: Jublia (12 ml, antifungal): U.S. GoodRx price $2,236.00, U.S. Amazon price $2,502.10, Canadian pharmacy average $257.77 – 89% savings. Xifaxan (550 mg, treats IBS): U.S. GoodRx price $10,036.00, U.S. Amazon price $11,233.90, Canadian pharmacy average $2,325.78 – 78% savings. Myrbetriq (50 mg, treats overactive bladder): U.S. GoodRx price $1,129.00, U.S. Amazon price $994.78, Canadian pharmacy average $314.57 – 70% savings. Additional drugs researched in the study included Xarelto, Jardiance, Rybelsus, Farxiga, Trintellix, Premarin, and Eliquis. The full comparison chart of the 10 popular prescription medications is at https://shorturl.at/odDrW. "With U.S. drug prices being less affordable for millions, this study shows personal prescription importation from licensed Canadian pharmacies remains a proven lifeline that is available today," said Hunter. "Our data shows consumers can slash costs on essential brand-name medications, allowing them to prioritize health without financial ruin. This transforms lives, and Americans should know they have this safe, reliable option." For more information on safe importation and to join (for free) the fight for affordable medications, visit www.PersonalImportation.org. Methodology: Prices obtained Mar. 2026 for 90-day supplies. Amazon pricing is for delivery to N.J.; GoodRx pricing is from N.J. pharmacies using cash price with the lowest after-coupon discount price; Canadian mail-order pricing uses the average of a cross-section of pharmacies certified by Canadian International Pharmacy Assn. (CIPA.com) and is for Health Canada-approved, brand-name products dispensed by a pharmacy licensed in Canada. Savings based on average of GoodRx and Amazon prices. At time of survey, Rybelsus 7 mg was priced but unavailable at Amazon. All registered trademarks referred to herein belong to their respective owners. About CPPI: The Campaign for Personal Prescription Importation (CPPI), based in Hillsborough, N.J., is a national nonprofit patient advocacy organization fighting for Americans' access to safe, affordable prescription medications from Canada for personal use. Tens of millions of Americans – especially the elderly and others on fixed incomes – struggle to pay the extremely high prices of prescription medications in the U.S. CPPI is their voice. For more information and to join us: www.PersonalImportation.org.

17 Mar 2026

·www.drugs.com

Recommendations Presented for Management of Hepatic Encephalopathy

TUESDAY, March 17, 2026 -- In a clinical guideline issued by the American College of Gastroenterology and published in the March issue of the American Journal of Gastroenterology , recommendations are presented for the diagnosis and management of hepatic encephalopathy (HE). Jasmohan S. Bajaj, M.D., from the Virginia Commonwealth University and Richmond VA Medical Center, and colleagues present 24 recommendations for the diagnosis, management, and prevention of HE. According to the recommendations, for patients being assessed for covert and minimal HE (CHE and MHE), a single-test strategy is suggested over a two-test combination strategy, and serum ammonia levels alone are not suggested to make the diagnosis. The evidence is insufficient to recommend for or against routine treatment of MHE/CHE for preventing overt HE (OHE). Treatment with lactulose is suggested versus no treatment in patients with MHE/CHE. Routine testing of serum ammonia is not suggested for guiding HE treatment decisions for inpatients with HE. To improve inpatient outcomes and prevent recurrence of OHE episodes, treatment with lactulose is recommended. Treatment with high-volume polyethylene glycol preparations is suggested as an alternative to lactulose in inpatients with OHE. Rifaximin is suggested as an addition to lactulose therapy in inpatients with acute OHE. For prevention of recurrence after an initial episode of OHE, lactulose titrated to two to three soft bowel movements daily is recommended as outpatient first-line therapy. Rifaximin therapy is suggested in the outpatient setting to prevent HE recurrence in patients with cirrhosis and OHE. "Although current diagnostic and management strategies have made major strides, gaps remain in the appropriate identification of HE and to treat patients who are not responsive to currently available therapies," the authors write. Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text

100 Deals associated with Rifaximin

External Link

KEGG	Wiki	ATC	Drug Bank
D02554	Rifaximin	D06AX11 A07AA11	DB01220

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperammonemia	Japan	ASKA Pharmaceutical Co., Ltd.	28 Sep 2016
Irritable bowel syndrome with diarrhea	United States	Salix Pharmaceuticals, Inc.	27 May 2015
Hepatic Encephalopathy	Australia	Norgine Pty Ltd.	17 May 2012
Turista	United States	Salix Pharmaceuticals, Inc.	25 May 2004
Diarrhea	China	Alfa Wassermann SpA	23 Dec 2002
Irritable Bowel Syndrome	China	Alfa Wassermann SpA	23 Dec 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ascites	Phase 3	France	Alfasigma SpA	05 Jun 2018
Fibrosis	Phase 3	France	Alfasigma SpA	05 Jun 2018
Spontaneous bacterial peritonitis	Phase 3	France	Alfasigma SpA	05 Jun 2018
Crohn Disease	Phase 3	United States	Bausch Health Americas, Inc.	21 Aug 2014
Acute diarrhea	Phase 3	United States	Bausch Health Americas, Inc.	01 Dec 2005
Clostridium difficile diarrhea	Phase 3	United States	Bausch Health Americas, Inc.	01 Dec 2005
Clostridium Infections	Phase 3	United States	Bausch Health Americas, Inc.	01 Dec 2005
Dementia, Vascular	Phase 2	United States	Bausch Health Americas, Inc.	30 Dec 2024
Hemoglobin SC Disease	Phase 2	United States	Bausch Health Americas, Inc.	22 Mar 2022
Hemoglobin SC Disease	Phase 2	Canada	Bausch Health Americas, Inc.	22 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03069131 (Pubmed \| J Hepatol)	Phase 3	-	152	Rifaximin 550 mg BID	uykfhyyido(txetithofw) = jpwziffhfb ytmkfzadxh (ehjvgiiovg, 43.5 - 67.8) View more	Negative	01 Dec 2025
				Placebo BID	uykfhyyido(txetithofw) = uszyhkyyer ytmkfzadxh (ehjvgiiovg, 56.2 - 78.7) View more
NCT06852274 (Pubmed \| Int J Colorectal Dis)	Not Applicable	Diverticulosis, Colonic	70	Clostridium butyricum CBM588	mbzhqujiyy(mvuyblqzmd) = xcgwljmmdw kmkpxzqrlu (owasfojfxa ) View more	Positive	18 Oct 2025
				Rifaximin	mbzhqujiyy(mvuyblqzmd) = dkaespxwgx kmkpxzqrlu (owasfojfxa ) View more
MDS2025	Phase 2	Dyskinesia, Drug-Induced	16	Rifaximin	wqowdmytya(vftpjapdrs) = gmijudihgp jztjveipqk (oxfhnghnpb ) View more	Negative	05 Oct 2025
				Placebo	wqowdmytya(vftpjapdrs) = lhajgzypkl jztjveipqk (oxfhnghnpb ) View more
NCT04249622 (CTgov)	Phase 2	HER2 Positive Breast Cancer	20	Questionnaire Administration+Rifaximin (Arm I (Rifaximin, Pertuzumab-based Chemotherapy))	jlhiqoslnp = rehguhcbrl pgxzjkunni (hqyvydmvqz, djpbprppgl - saoezqtimr) View more	-	07 Aug 2025
				Questionnaire Administration (Arm II (Pertuzumab-based Chemotherapy))	aqzmsjrawb = tncgowihsy dyylkjwdcz (zjzoconfjd, zlnfozpsce - dotbmgedci) View more
Company_Website Manual	Not Applicable	Hepatic Encephalopathy	-	Xifaxan	delwwqedzb(ezvybpkqtd): P-Value = <0.05	Positive	06 May 2025
				lactulose
NCT03219528 (CTgov)	Phase 4	Irritable Bowel Syndrome	74	Rifaximin 550 MG (Rifaximin)	sqlnwuyjzb(buukpejqek) = mhepzvlnxb rxsuamntmz (evyjodoyuj, 1.8) View more	-	27 Apr 2025
				Low FODMAP Diet (Low FODMAP Group)	sqlnwuyjzb(buukpejqek) = cxbytxagte rxsuamntmz (evyjodoyuj, 1.6) View more
NCT05098028 (CTgov)	Phase 2	Hemoglobin SC Disease \| Anemia, Sickle Cell	44	Low Dose Rifaximin ER (Low Dose Rifaximin ER)	ekurrxzwma(ajxvnxizzz) = jumcqgayym wygggyujmx (aiaknjkudz, 86.3) View more	-	19 Sep 2024
				High Dose Rifaximin ER (High Dose Rifaximin ER)	ekurrxzwma(ajxvnxizzz) = bmnxhvoobn wygggyujmx (aiaknjkudz, 58.4) View more
PHASE II TRIAL OF RIFAXIMIN (DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024)	Phase 2	HER2 Positive Breast Cancer HER2 positive	20	Rifaximin 550 mg BID	cfqvohneir(iiaiveenfb) = eimzqxjzjg abiftvtnir (xqbfrgvwuk ) View more	Positive	20 May 2024
NCT01345175 (CTgov)	Phase 3	Rectal Cancer	69	Rifaximin (Pts Receiving Rifaximin)	zgazkfdcvq = sodyezpfmc tavwqbgxyl (cjtdvfgqhc, pikycisrss - zpqjfbgsji) View more	-	14 May 2024
				Placebo (Pts Receiving Placebo)	zgazkfdcvq = rntrhmhmgk tavwqbgxyl (cjtdvfgqhc, oiiraoueuf - tkkxsfddld) View more
NCT05150587 (CTgov)	Phase 2	Rosacea	216	Rifaximin (Rifaximin 250 mg TID)	fkeumxtcjt(zmyatedarn) = qbfkbluqhg khfouehwrv (oflpwzkmzi, 9.24) View more	-	24 Apr 2024
				Rifaximin (Rifaximin 500 mg TID)	fkeumxtcjt(zmyatedarn) = imsunfdupc khfouehwrv (oflpwzkmzi, 14.78) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rifaximin

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation